Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

The pipeline will run for about 213 kilometres to a $7.4 billion polyethylene plant where construction started last September ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...